Effects of tramadol on synovial fluid concentrations of substance P and interleukin-6 in patients with knee osteoarthritis: comparison with paracetamol

被引:25
作者
Bianchi, M
Broggini, M
Balzarini, P
Baratelli, E
Ferrario, P
Panerai, AE
Sacerdote, P
机构
[1] Univ Milan, Dept Pharmacol, I-20129 Milan, Italy
[2] Osped Circolo Varese, Rheumatol Unit, I-21100 Varese, Italy
[3] Fdm Macchi, I-21100 Varese, Italy
关键词
interleukin-6; osteoarthritis; paracetamol; synovial fluid; substance P; tramadol;
D O I
10.1016/j.intimp.2003.08.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Both the analgesic drugs tramadol and paracetamol are widely used for the symptomatic therapy of osteoarthritis (OA). The aim of this double-blind, randomised study in patients with knee OA was to compare their effects on synovial fluid concentrations of interleukin (IL)-6 and substance P (SP). Moreover, we evaluated plasma and synovial fluid concentrations of tramadol and its active metabolite (O-desmethyl-tramadol, M1) after oral treatment with this drug. Twenty patients were enrolled. A group of 10 patients received tramadol (50 mg three times a day), and another group of 10 patients were treated with paracetamol (500 mg three times a day) for 7 days. Both drugs significantly reduced the intensity of joint pain. The synovial fluid concentrations of SP were significantly reduced only by the treatment with tramadol. In this group of patients, IL-6 synovial fluid concentrations were slightly, but not significantly, decreased. Paracetamol did not significantly change the synovial fluid concentrations of SP and IL-6. After oral administration, a considerable amount of tramadol was measurable in synovial fluid. Both in plasma and synovial fluid the concentrations of M1 were markedly lower than those of tramadol, with a T/M1 ratio of 14.7 +/- 4.6 and 9.3 +/- 3.9, respectively. These data demonstrate that the activity of tramadol may involve the modulation of inflammatory mediators. Moreover, they indicate that after oral treatment with tramadol, both the parent drug and its active metabolite can penetrate into synovial fluid. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:1901 / 1908
页数:8
相关论文
共 42 条
  • [1] Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905
  • [2] ALTMAN RD, 1987, SCAND J RHEUMATOL, P31
  • [3] The clinical use of tramadol hydrochloride
    Bamigbade, TA
    Langford, RM
    [J]. PAIN REVIEWS, 1998, 5 (03): : 155 - 182
  • [4] Effects of tramadol on experimental inflammation
    Bianchi, M
    Rossoni, G
    Sacerdote, P
    Panerai, AE
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (02) : 220 - 225
  • [5] Bianchi MFP, 2002, ANALGESIA, V6, P39
  • [6] Tramadol anti-inflammatory activity is not related to a direct inhibitory action on prostaglandin endoperoxide synthases
    Buccellati, C
    Sala, A
    Ballerio, R
    Bianchi, M
    [J]. EUROPEAN JOURNAL OF PAIN, 2000, 4 (04) : 413 - 415
  • [7] The visual analogue pain intensity scale: what is moderate pain in millimetres?
    Collins, SL
    Moore, RA
    McQuay, HJ
    [J]. PAIN, 1997, 72 (1-2) : 95 - 97
  • [8] The pharmacology of tramadol
    Dayer, P
    Desmeules, J
    Collart, L
    [J]. DRUGS, 1997, 53 (Suppl 2) : 18 - 24
  • [9] Osteoarthritis: New insights - Part 2: Treatment approaches
    Felson, DT
    Lawrence, RC
    Hochberg, MC
    McAlindon, T
    Dieppe, PA
    Minor, MA
    Blair, SN
    Berman, BM
    Fries, JF
    Weinberger, M
    Lorig, KR
    Jacobs, JJ
    Goldberg, V
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (09) : 726 - 737
  • [10] Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee - A randomized trial
    Geba, GP
    Weaver, AL
    Polis, AB
    Dixon, ME
    Schnitzer, TJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (01): : 64 - 71